Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

AXSM Axsome Therapeutics Inc

123,00

-1,41 (-1,13%)

Vor Marktöffnung

Zuletzt aktualisiert: 14:53:52

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Axsome Therapeutics Charts.

Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Axsome Therapeutics Charts.

News Axsome Therapeutics Inc

Form 8-K - Current report
Mittwoch 5 März 2025 (2 Tage vor) • Edgar (US Regulatory)

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Mittwoch 5 März 2025 (2 Tage vor) • GlobeNewswire Inc.

Form 8-K - Current report
Montag 3 März 2025 (4 Tage vor) • Edgar (US Regulatory)

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Montag 3 März 2025 (4 Tage vor) • GlobeNewswire Inc.

Axsome Therapeutics to Participate in Upcoming Investor Conferences
Mittwoch 26 Februar 2025 (1 Woche vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 26 Februar 2025 (1 Woche vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 26 Februar 2025 (1 Woche vor) • Edgar (US Regulatory)

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
Montag 24 Februar 2025 (2 Wochen vor) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dienstag 18 Februar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 18 Februar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dienstag 18 Februar 2025 (2 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 15 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Weitere Axsome Therapeutics Inc News-Artikel

France Emprunt D Etat Go...

Orange Domestic bond 0.7...

Intesa Sanpaolo

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen